Added to YB: 2026-01-06
Pitch date: 2026-01-03
OVID [bullish]
Ovid Therapeutics Inc.
Author Info
JNap is Head of Research for Remsen Investors LP, a long/short biopharma fund and owner of Bio5C, an independent biopharma research service. Sign up for the newsletter.
Company Info
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States.
Market Cap
$229.1M
Pitch Price
$1.76
Price Target
N/A
Dividend
N/A
EV/EBITDA
-5.96
P/E
-3.49
EV/Sales
32.87
Sector
Biotechnology
Category
growth
Six Lottos For 2026 - Ovid Therapeutics Inc.
OVID (lotto play): GABA-AT inhibitor OV329 shows biologic activity in Phase 1, higher-dose data Q1 2026, Phase 2 mid-2026. Provides ~$210M downside floor vs $500M+ opportunity. Real upside: KCC2 activators OV350/OV4071 for neurological disorders. Dec 2025 Phase 1 data positive, oral Phase 1 Q2 2026. Multi-billion TAMs if 20X lotto pays off.
Read full article (2 min)